194 related articles for article (PubMed ID: 38113419)
1. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
[TBL] [Abstract][Full Text] [Related]
2. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
3. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
5. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
6. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor Microenvironment.
Yeo YY; Qiu H; Bai Y; Zhu B; Chang Y; Yeung J; Michel HA; Wright K; Shaban M; Sadigh S; Nkosi D; Shanmugam V; Rock P; Tung Yiu SP; Cramer P; Paczkowska J; Stephan P; Liao G; Huang AY; Wang H; Chen H; Frauenfeld L; Mitra B; Gewurz BE; Schürch CM; Zhao B; Nolan GP; Zhang B; Shalek AK; Angelo M; Mahmood F; Ma Q; Burack WR; Shipp MA; Rodig SJ; Jiang S
bioRxiv; 2024 Mar; ():. PubMed ID: 38496566
[TBL] [Abstract][Full Text] [Related]
8. Digital spatial profiling of CD4
Takeuchi M; Miyoshi H; Semba Y; Yamada K; Nakashima K; Sato K; Furuta T; Moritsubo M; Ogura Y; Tanaka K; Imamoto T; Arakawa F; Kohno K; Ohshima K
Virchows Arch; 2023 Aug; 483(2):255-260. PubMed ID: 37270432
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma.
Martynchyk A; Chowdhury R; Hawkes EA; Keane C
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958391
[TBL] [Abstract][Full Text] [Related]
10. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract][Full Text] [Related]
11.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
12. Mass cytometry of Hodgkin lymphoma reveals a CD4
Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
Chan FC; Mottok A; Gerrie AS; Power M; Nijland M; Diepstra A; van den Berg A; Kamper P; d'Amore F; d'Amore AL; Hamilton-Dutoit S; Savage KJ; Shah SP; Connors JM; Gascoyne RD; Scott DW; Steidl C
J Clin Oncol; 2017 Nov; 35(32):3722-3733. PubMed ID: 28898161
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
Liu Y; Ping L; Song Y; Tang Y; Zheng W; Liu W; Ying Z; Zhang C; Wu M; Feng F; Lin N; Tu M; Zhu J; Xie Y
BMC Med; 2024 Mar; 22(1):107. PubMed ID: 38454451
[TBL] [Abstract][Full Text] [Related]
16. The role of IgG4-positive plasma cell population in classic Hodgkin lymphoma.
Guler B; Tekden BC; Cetin G; Yildiz P; Turna S; Uysal O; Sinal I
J Hematop; 2023 Dec; 16(4):191-197. PubMed ID: 38175429
[TBL] [Abstract][Full Text] [Related]
17. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.
Georgoulis V; Papoudou-Bai A; Makis A; Kanavaros P; Hatzimichael E
Biology (Basel); 2023 Jun; 12(6):. PubMed ID: 37372147
[TBL] [Abstract][Full Text] [Related]
20. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.
Le-Nguyen A; Rys RN; Petrogiannis-Haliotis T; Johnson NA
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1432. PubMed ID: 34047076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
